Search - tctmd.com

Displaying 81 - 100 of 218

Sort: Relevancy | Date

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

April 27, 2018

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

April 24, 2018

Abciximab in ‘Short Supply’ Worldwide

News Daily News

Abciximab in ‘Short Supply’ Worldwide

April 13, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

News Daily News

Meta-analysis Supports Benefits of Short-term DAPT Among Elderly Patients

Yael L. Maxwell

February 20, 2018

Could NOACs Have a Role for Secondary Prevention After STEMI?

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

February 08, 2018

Women Have Higher Risk of Unplanned Readmission After PCI

News Daily News

Women Have Higher Risk of Unplanned Readmission After PCI

Michael O'Riordan

January 12, 2018

Coronary Embolism in STEMI Is Rare but Warrants a Unique Approach

News Daily News

Coronary Embolism in STEMI Is Rare but Warrants a Unique Approach

January 11, 2018

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

September 01, 2017

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

Cardiac Complications of Cancer: Arterial Thromboembolism Risk Doubles With Incident Diagnosis

News Daily News

Cardiac Complications of Cancer: Arterial Thromboembolism Risk Doubles With Incident Diagnosis

Yael L. Maxwell

August 14, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.